posted on 2023-03-31, 01:22authored byStephanie Rossnagl, Hiba Ghura, Christopher Groth, Eva Altrock, Franz Jakob, Sarah Schott, Pauline Wimberger, Theresa Link, Jan Dominik Kuhlmann, Arnulf Stenzl, Jörg Hennenlotter, Tilmann Todenhöfer, Markus Rojewski, Karen Bieback, Inaam A. Nakchbandi
<p>Supplementary-Figure 5 Flow cytometry of MSC markers in human bone marrow biopsies Bone marrow aspirates from patients with prostate cancer (A) and breast cancer (B) who had an evaluation of their bone marrows for the presence of cytokeratin-stained cells to detect disseminated cancer cells (DTCs) were stained for the various MSC markers and analyzed by flow cytometry. The expression of the following markers was not different between cytokeratin negative or positive biopsies: MSCA1, Stro1, CD146, FAP, CD44, CD144, CD73, CD349, CD56 and CD140b in prostate cancer biopsies, n=15/21 (A) and MSCA1, Stro1, CD146, FAP, CD44, CD73 and CD349 in breast cancer biopsies, n=30/30 (B). (C) To exclude any effect of neoadjuvant chemotherapy on the MSC population, the breast cancer patient samples were divided into samples from patients with or without neoadjuvant chemotherapy. Both groups showed an increase in the MSC subpopulation in samples without evidence of cytokeratin-stained cells in bone marrow, n= 10/11/20/19.</p>